Cardiol Therapeutics (CRDL) Income from Continuing Operations (2020 - 2026)
Cardiol Therapeutics' (CRDL) quarterly Income from Continuing Operations came in at 6931880.35 in Q1 2026, down 21.58% YoY from 8839830.89 in Q1 2025, and down 21.58% on a QoQ basis from 5701330.13 in Q1 2025.
Cardiol Therapeutics (CRDL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Cardiol Therapeutics (CRDL) has 6 years of Income from Continuing Operations data on file, last reported at 6931880.35 in Q1 2026.
- Quarterly Income from Continuing Operations fell 21.58% year-over-year to 6931880.35 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24972549.44 (up 10.42% YoY) and the FY2025 annual result came in at 24086852.95, up 13.91% from the prior year.
- Income from Continuing Operations retreated to 6931880.35 in Q1 2026, from 5701330.13 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 5701330.13 in Q1 2025 to a low of 9837989.19 in Q3 2022.
- A 4-year average of 7081763.99 and a median of 6931880.35 in 2026 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 39.64% in 2022, down 36.24% in 2022.
- Tracing CRDL's Income from Continuing Operations over 4 years: stood at 6381515.36 in 2022, then advanced by 6.64% to 5957823.61 in 2024, then rose by 4.31% to 5701330.13 in 2025, then retreated by 21.58% to 6931880.35 in 2026.
- The last three Income from Continuing Operations figures came in at 6931880.35 (Q1 2026), 5701330.13 (Q1 2025), and 5957823.61 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Cardiol Therapeutics | 212.63 Mn | 193.78 Mn | - | -5.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.93 Mn |
| Mar 31, 2025 | -5.70 Mn |
| Mar 31, 2024 | -5.96 Mn |
| Dec 31, 2022 | -6.38 Mn |
| Sep 30, 2022 | -9.84 Mn |
| Jun 30, 2022 | -7.09 Mn |
| Mar 31, 2022 | -7.67 Mn |
| Dec 31, 2021 | -10.57 Mn |
| Sep 30, 2021 | -8.05 Mn |
| Jun 30, 2021 | -5.20 Mn |
| Mar 31, 2021 | -7.08 Mn |
| Dec 31, 2020 | -7.36 Mn |
| Sep 30, 2020 | -3.29 Mn |
| Jun 30, 2020 | -2.57 Mn |